[HTML][HTML] TIM-3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma

F Yang, Z Zeng, J Li, X Ren, F Wei - Frontiers in Molecular …, 2021 - frontiersin.org
Background: T-cell Immunoglobulin and Mucin domain-containing molecule-3 (TIM-3) is a
new immune checkpoint molecule which plays important and complex roles in regulating …

[HTML][HTML] TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

N Sauer, N Janicka, W Szlasa, B Skinderowicz… - Cancer Immunology …, 2023 - Springer
T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression has been
a trending topic in recent years due to its differential expression in a wide range of …

[HTML][HTML] Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer

JF Liu, L Wu, LL Yang, WW Deng, L Mao, H Wu… - Journal of Experimental …, 2018 - Springer
Background T-cell immunoglobulin mucin 3 (TIM3) is a negative immune checkpoint and
plays a crucial part in tumor-induced immune suppression. However, the mechanism of …

[HTML][HTML] Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and database evaluation

S Qin, B Dong, M Yi, Q Chu, K Wu - Frontiers in oncology, 2020 - frontiersin.org
Background: T cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3), a
novel emerging immune checkpoint molecule, was reported to express both on various …

[HTML][HTML] TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3β/Snail signaling …

B Shan, H Man, J Liu, L Wang, T Zhu… - Oncology …, 2016 - spandidos-publications.com
T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), a negative regulator
of antitumor immune response, has been demonstrated to be involved in the onset and …

[HTML][HTML] TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: a meta-analysis and bioinformatics validation

K Zang, L Hui, M Wang, Y Huang, X Zhu… - Frontiers in oncology, 2021 - frontiersin.org
Background As a novel immune checkpoint molecular, T-cell immunoglobulin mucin 3 (TIM-
3) is emerging as a therapeutic target for cancer immunotherapy. However, the predictive …

TIM-3 participates in the invasion and metastasis of nasopharyngeal carcinoma via SMAD7/SMAD2/SNAIL1 axis-mediated epithelial-mesenchymal transition

Y Xiao, J Qing, B Li, L Chen, S Nong… - OncoTargets and …, 2020 - Taylor & Francis
Background T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) was
originally found to negatively regulate immune response and mediate immune escape in …

[HTML][HTML] Tim-3 expression in cervical cancer promotes tumor metastasis

Y Cao, X Zhou, X Huang, Q Li, L Gao, L Jiang… - PloS one, 2013 - journals.plos.org
Background T cell immunoglobulin mucin-3 (Tim-3) has been identified as a negative
regulator of anti-tumor immunity. Recent studies highlight the important role of Tim-3 in the …

Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma

H Su, H Xie, C Dai, Y Ren, Y She, L Xu, D Chen, D Xie… - Lung Cancer, 2018 - Elsevier
Objectives T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising
checkpoint. However, its features and prognostic value in lung adenocarcinoma remain …

T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer

JF Liu, SR Ma, L Mao, LL Bu, GT Yu, YC Li… - Molecular …, 2017 - Wiley Online Library
T‐cell immunoglobulin mucin 3 (TIM 3) contributes to immune suppression during
progression of many cancers, but the precise role of TIM 3 in head and neck squamous cell …